Baseline visual field characteristics in the ocular hypertension treatment study

Johnson, Chris A.; Keltner, John L.; Cello, Kimberly E.; Edwards, Mary; Kass, Michael A.; Gordon, Mae O.; Budenz, Donald L.; Gaasterland, Douglas E.; Werner, Elliot B.

doi:10.1016/s0161-6420(01)00948-4

Cited by 73 publications

(43 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, perimetrists and patients should be made aware that during a typical examination, around 50% of the stimuli are not expected to be seen. Appropriate and standardised patient instructions produce reliable and usable results in the vast majority of patients 43 44…”

Section: Concepts That Erroneously Hinder the Use Of Sap To Measure Pmentioning

confidence: 99%

Practical recommendations for measuring rates of visual field change in glaucoma

Chauhan

Garway-Heath

Goñi³

et al. 2008

British Journal of Ophthalmology

435

385

View full text Add to dashboard Cite

To date, there has been a lack of evidence-based guidance on the frequency of visual field examinations required to identify clinically meaningful rates of change in glaucoma. The objective of this perspective is to provide practical recommendations for this purpose. The primary emphasis is on the period of time and number of examinations required to measure various rates of change in mean deviation (MD) with adequate statistical power. Empirical data were used to obtain variability estimates of MD while statistical modelling techniques derived the required time periods to detect change with various degrees of visual field variability. We provide the frequency of examinations per year required to detect different amounts of change in 2, 3 and 5 years. For instance, three examinations per year are required to identify an overall change in MD of 4 dB over 2 years in a patient with average visual field variability. Recommendations on other issues such as examination type, strategy and quality are also made.

show abstract

Section: Concepts That Erroneously Hinder the Use Of Sap To Measure Pmentioning

confidence: 99%

Practical recommendations for measuring rates of visual field change in glaucoma

Chauhan

Garway-Heath

Goñi³

et al. 2008

British Journal of Ophthalmology

435

385

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10][11][12][13][14] The Ocular Hypertension Treatment Study 15 showed that patients with OH on treatment who achieve a mean drop in IOP of 22% have a 4.4% risk of progression to glaucoma over five years compared with 9% without medication. This is an approximate 50% reduction in risk of progression to glaucoma with a 22% reduction in IOP.…”

Section: Case For Lowering Iopmentioning

confidence: 99%

“…A number of landmark studies [7][8][9][10][11][12][13][14][15] suggested that, especially in advanced glaucoma, IOP reduction of at least 30% should be sought. However, with currently available drugs, this is often unachievable with a single medication and many patients therefore require use of multiple drops or fixed-combination treatments.…”

Section: Case For Lowering Iopmentioning

confidence: 99%

Emerging Therapeutic Regimens for Glaucoma and Ocular Hypertension

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Glaucoma is the name given to a group of diseases characterized by incurable, progressive, multifactorial optic neuropathy. It is the second leading cause of blindness worldwide. Ocular hypertension (OH) is the term used to describe the presence of raised intraocular pressure (the most important risk factor for the development of glaucoma) in the absence of demonstrable glaucomatous optic neuropathy. The management of glaucoma and OH requires a holistic and rational approach, taking into account a number of factors. Treatment needs to be individualized depending on patient age, the severity and type of glaucoma, associated medical conditions, the condition of the ocular surface, tolerability of topical medication, and patient wishes. An understanding of the mechanism of glaucoma and its etiology in a particular patient is crucial for the initiation of appropriate treatment. This review article summarizes the existing medical management of glaucoma and OH, including pharmacology, mode of action, and safety profile for each major group of medication, and reviews current advances and future developments in treatment for glaucoma, including experimental medications, together with a summary of their modes of action, pharmacology, and safety profiles. It is hoped that readers will become more aware of the evolution of the next generation glaucoma and OH medications.

show abstract

“…Similarly, on multivariate analysis an increased pattern standard deviation (per 0.2 dB greater) on achromatic visual field testing was associated with an hazard ratio of 1.27 (95% CI 1.06-1.52). Functional loss detected by short-wavelength automated perimetry was present in 20% of patients at OHTS baseline, suggesting that perhaps some patients with existing glaucoma damage were enrolled [26].…”

Section: Progression From Ocular Hypertension To Primary Open-angle Gmentioning

confidence: 99%

Evolving global risk assessment of ocular hypertension to glaucoma

Fechtner¹,

Khouri²

2007

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

Baseline visual field characteristics in the ocular hypertension treatment study

Cited by 73 publications

References 10 publications

Practical recommendations for measuring rates of visual field change in glaucoma

Practical recommendations for measuring rates of visual field change in glaucoma

Emerging Therapeutic Regimens for Glaucoma and Ocular Hypertension

Evolving global risk assessment of ocular hypertension to glaucoma

Contact Info

Product

Resources

About